<div id="readability-page-1"><p><strong>GSK PLC Sponsored ADR</strong> (NYSE:GSK - Get Free Report) declared a quarterly dividend on Wednesday, October 29th. Shareholders of record on Friday, November 14th will be given a dividend of 0.4171 per share by the pharmaceutical company on Thursday, January 8th. This represents a c) dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend is Friday, November 14th.</p><ul><li>Merck: 4 No-Brainer Reasons to Buy This Dip </li></ul><p>GSK has a payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect GSK to earn $4.65 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 37.0%. </p><h2>GSK Stock Up 2.4%</h2><p>GSK stock traded up $1.08 during midday trading on Thursday, hitting $47.01. 6,338,183 shares of the stock were exchanged, compared to its average volume of 5,192,395. GSK has a 1 year low of $31.72 and a 1 year high of $47.16. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a market cap of $95.56 billion, a P/E ratio of 21.76, a P/E/G ratio of 1.97 and a beta of 0.53. The company has a 50 day moving average price of $41.81 and a two-hundred day moving average price of $39.59. </p><ul><li>After a Reset Year, Is Moderna Stock Poised for a Comeback?</li></ul><p>GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.26 by $0.22. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $11.35 billion for the quarter, compared to analyst estimates of $8.21 billion. During the same quarter in the previous year, the business posted $0.50 EPS. The firm's revenue was up 6.7% compared to the same quarter last year.  GSK has set its FY 2025 guidance at 4.730-4.810 EPS. On average, sell-side analysts predict that  GSK will post 4.14 earnings per share for the current fiscal year. </p><h2>GSK Company Profile</h2> (Get Free Report)<p>GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&amp;D.</p><h2>See Also</h2><ul><li>Five stocks we like better than GSK</li><li>How to Invest in Insurance Companies: A Guide </li><li>Carrier Stock Looks Undervalued After Earnings Surprise</li><li>What is the Dogs of the Dow Strategy? Overview and Examples</li><li>Alphabet Crushes Q3 Earnings, Reports First $100 Billion Quarter</li><li>What Are Dividend Contenders? Investing in Dividend Contenders</li><li>Rocket Lab Stock Dips 14%—Buying Opportunity Ahead?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/DividendChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/DividendChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw"/></p><ul><li>Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in GSK Right Now?</h2><p>Before you consider GSK, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.</p><p>While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GSK.WI

<p>GSK PLC Sponsored ADR (NYSE:GSK) announced a quarterly dividend of $0.4171 per share, payable on January 8, 2024, to shareholders of record on November 14, 2023. This dividend yields 3.5% annually. GSK's payout ratio is 35.5%, indicating strong earnings coverage for the dividend. The company reported $1.48 EPS for the last quarter, exceeding estimates, with revenue of $11.35 billion, up 6.7% year-over-year. GSK's stock rose 2.4% to $47.01, with a market cap of $95.56 billion and a P/E ratio of 21.76.</p>

GSK PLC Sponsored ADR Plans Quarterly Dividend of $0.42 (NYSE:GSK)